anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim: To assess the feasibility of video game-based trunk exercises using the Valedo® system in a chronic stroke population. Method: Ten chronic stroke survivors (eight males and two females, mean age 63 ± 15 years) were asked to complete 18 intervention sessions, each lasting 45 min., over 6-8 weeks. Feasibility was evaluated quantitatively using the Psychosocial Impact of Assistive Devices Scale (PIADS) as well as through recruitment, retention, adherence, and safety measures. Qualitative data on feasibility were collected through post-intervention semi-structured interviews. Descriptive analysis was used to summarize participant characteristics, recruitment, retention, and adherence. Qualitative data were analyzed using thematic analysis of the interviews. Results: Twelve stroke survivors were recruited from Southampton (United Kingdom) and Riyadh (Kingdom of Saudi Arabia), with two participants dropping out after the baseline assessment session. The remaining ten participants completed the study with a mean adherence of 96.11% to the planned sessions. No serious adverse effects were reported, however, four participants did experience trunk muscle tightness and fatigue. Post-intervention interviews revealed that participants encountered some physical and cognitive challenges while playing the Valedo video games. However, they felt that the implementation of trunk exercises using video games was safe, as the exercises were performed in a secure environment and in safe positions. Conclusions: The findings suggest that the Valedo system is feasible for delivering trunk exercises to chronic stroke survivors. Several factors should be considered when implementing this type of intervention in the future.
A total of 1000 children aged 3-12 years who applied to the Department of Pedodontics, Faculty of Dentistry, Ege University for routine dental examination were enrolled the study. From these group, children with BS (n=44) were selected as the study group. With the same number of the study group, with the same age and same sex, children without BS (n=44) were categorized as the control group. The parents were interviewed based on a structured questionnaire including questions on the socioeconomic status of the family, the oral hygiene and dietary habits of the children, medical and dental history of the children. The presence and grading of BS, dental caries incidence and dental plaque index scores were recorded by the same pediatric dentist (G.İ.). Dental examinations of the children were conducted under natural light with the aid of a dental mirror and explorer. Dental caries scores were recorded according to WHO (World Health Organization) criteria using DMFT/DMFS (decay, missing, filled, tooth/surface in permanent teeth) and dmft/dmfs indices (decay, missing, filled, tooth/surface in primary teeth). All children were classified according to the DMFT/dmft scores; Group-1: caries active (dmft+DMFT≥1), Group-2: caries-free (dmft+DMFT=0). Dental plaque scores were recorded according to Silness \& Löe index. The BS scores were classified according to Gasparetto et al. The plaque samples were dispersed in a vortex mixer to obtain a homogeneous suspension and cultivated on selective VCAT medium (Oxoid) for Capnocytophaga spp., mitis salivarius agar (Difco) with 15% sucrose (Difco) and 0.2 units/mL of bacitracin (Sigma, Sigma-Aldrich Co., St Louis, MO, USA) for S. mutans , MRS Agar was used for the isolation of lactobacilli spp. (ref) and Actinomyces Selective Agar was used for the isolation of Actinomyces spp.

All data were analyzed by SPPS 25.0 (SPSS Statistics for Windows, Armonk, NY: IBM Corp.). In the analysis of data, t test and Mann Whitney-U test were used for the comparison of the two groups. Categorical data were analyzed by Fisher's Exact Test and chi square test. For the significance level of the tests, p\<0.05 and p\<0.01 were accepted.
New evidence-based treatments have been slow to be adopted into the routine practice of addiction treatment, and traditional training methods are of limited effectiveness. In this study, the investigators propose to continue development of methods for training clinicians in Motivational Interviewing (MI), based on the principle of live supervision. Live supervision (supervisor and trainee seeing a patient together) is common in basic training, but rarely used in continuing education. In the initial funding period we developed Teleconference Supervision (TCS), which implements live supervision by an expert through teleconferencing technology, harnessing the principles of context-dependent learning, differential reinforcement with immediacy of feedback, and modeling. Clinicians interview standard patients at their home clinics, while Supervisors listen via telephone. The clinician wears an earpiece, through which the Supervisor provides immediate feedback and coaching designed to differentially reinforce and shape MI skills. In a randomized controlled trial with community clinicians (N= 100), TCS produced superior overall MI skill, compared to control conditions where clinicians received Workshop only training, or standard tape-based supervision. Findings were encouraging yet the proportion of clinicians achieving expert proficiency was limited, and there were trends toward loss of skill at follow-up, suggesting longer training is needed to maximize and sustain MI skill.

In the new funding period, the investigators propose to build and improve upon TCS by testing an extended model of Teleconference Supervision (TCS-Plus), which will preserve the elements of live supervision from an expert supervisor but will also provide 4 sessions of enhanced tape review supervision on a bi-weekly basis after the initial TCS training. Using telephone technology, enhanced taped review allows the Supervisor and Clinician to listen to the taped session together before discussing the session. Practice sessions will increase from 5 to 9 and be spread out from 8 to 16 weeks. Providing both TCS and enhanced tape review supervision maximizes supervision style advantages. While both offer context dependent learning, TCS provides for modeling and differential reinforcement with immediacy of feedback, and enhanced tape review provides ample time to role play and discuss technique. TCS-Plus will be compared to standard Tape Review supervision. The proposed project will be a StageI trial, intent on maximizing the gains already detected with the TCS model. The investiators will assess if TCS-Plus produces superior MI skill to standard Tape Review supervision in a randomized trial with 130 community based-clinicians. It is hoped that, if successful, TCS-Plus could be a model for remote training and supervision at community treatment programs, promoting adoption of a variety of evidence-based treatments for substance use disorders into routine practice.
The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
This is a single-center, double-blind, randomized, multiple-dose, parallel trial with a total duration of up to 50 days. The trial population will consist of healthy volunteers. Eligible subjects will be randomized to receive either subcutaneous (SC) apraglutide or matching placebo. The effect of apraglutide on gastric emptying of liquids will be assessed by the measure of PK of acetaminophen mixed with a liquid meal.

There will be two treatment periods, occurring according to the same sequence. In Period 1 acetaminophen will be given on Day 1, apraglutide/placebo will be injected on Day2. In Period 2 apraglutide/placebo will be injected on Day 9 and acetaminophen will be given on Day 10. This will allow to assess the PK of acetaminophen without the effect of apraglutide in Period 1, and to assess the PK of acetaminophen at the maximum concentration of apraglutide in Period 2.
PROBLEM TO BE SOLVED: To obtain an antifungal agent having high safety without being affected by pH or other formulation ingredient and obtain an antimicrobial low-irritative cosmetic exhibiting sufficient antimicrobial activity, having high safety and having not only low irritation to skin, but also free from uncomfortable feeling even when used. SOLUTION: This antifungal agent comprises one or two or more kinds of compounds selected from an acylcarnitine represented by formula (1) and its salt. This antimicrobial low-irritative cosmetic comprises the above antifungal agent and (A) one or two or more kinds of compounds selected from a group consisting of para-oxybenzoic acid ester, phenoxyethanol, light-sensitive element No. 101, light-sensitive element No. 201, light-sensitive element No. 401, hinokithiol, N-long-chain acyl basic amino acid derivative and its acid addition salt and/or (B) one or two or more kinds of antimicrobial plant extracts.
Discontinuation symptoms have been systematically evaluated in patients taking duloxetine. Following abrupt or tapered discontinuation in adult placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue.

During marketing of other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Although these events are generally self-limiting, some have been reported to be severe.

Patients should be monitored for these symptoms when discontinuing treatment with Duloxetine delayed-release capsules. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [see Dosage and Administration (2.7)].
The invention belongs to the technical field of cosmetics, and particularly relates to chlorine-removing antiallergic shower gel and a preparation method thereof. The invention provides a chlorine-removing antiallergic shower gel, which comprises a chlorine-removing composition, a moisturizing antiallergic composition, a surfactant, a regulator and water. The chlorine removal composition comprises chlorine removal materials and an auxiliary agent A; the moisturizing antiallergic composition comprises a plant extract and an auxiliary agent B. The chlorine removal material is sodium thiosulfate, and the auxiliary agent A is one or two selected from D-panthenol and vitamin E acetate. The plant extract comprises aloe leaf juice and kuh-seng extract, and the auxiliary agent B comprises betaine, polyalcohol and stearoyl lactylate. The product of the invention can effectively clean the skin, remove residual chlorine remained on the skin, simultaneously lighten the stimulation of the residual chlorine to the skin, and has the effects of relieving, calming, diminishing inflammation, preventing allergy and the like. The preparation method is simple and convenient, has strong repeatability and operability, and is beneficial to large-scale production.
Risk Summary

A published case report describes the presence of remdesivir and active metabolite GS-441524 in human milk. Available data (n=11) from pharmacovigilance reports do not indicate adverse effects on breastfed infants from exposure to remdesivir and its metabolite through breastmilk. There are no available data on the effects of remdesivir on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Data

Remdesivir and its metabolites were detected in the plasma of nursing rat pups, likely due to the presence of remdesivir and/or its metabolites in milk, following daily intravenous administration of remdesivir to pregnant rats from Gestation Day 6 to Lactation Day 20. Exposures in nursing pups were approximately 1% that of maternal exposure on Lactation Day 10. The concentration of remdesivir in animal milk does not necessarily predict the concentration of drug in human milk.
The present invention relates to huXAG-1, huXAG-2 and huXAG-3 proteins which are novel human growth factors. These proteins share homology with the XAG protein of Xenopus laevis and can be found in colon tissue. huXAG-1 is specifically found in cancerous colon cells and may therefore be a growth factor for colon cancer. In particular, isolated nucleic acid molecules are provided encoding the huXAG-1, huXAG-2 and huXAG-3 proteins. huXAG-1, huXAG-2 and huXAG-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of huXAG-1, huXAG-2 or huXAG-3 activity as well as diagnostic and therapeutic uses of the proteins.
As control group (CTRL), we will recruit a total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, "L. Vanvitelli" University of Campania (Naples, Italy).
The observational study recruits participants from clinics and communities with cognitive impairment. Healthy volunteers will also be recruited as controls. Longitudinal observation of these participants will help demonstrate AD biomarkers' significance during AD pathogenesis.

The investigators aim to build an aging population cohort covering the AD continuum and explore key biomarkers for AD. All participants will have multi-modal MRI scanning, PET scanning with different tracers, and blood test. With MRI scanning, the investigators are exploring the effect of neurovascular coupling in AD pathogenesis. In addition, the investigators are trying to find patterns/mapping of AD biomarkers with PET and blood tests. Beyond this, more neuroimage markers and digital biomarkers will be tested in the cohort.
Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
The treatment cycle in this study is 28 days. The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle. Subjects will be treated continuously until the criteria for termination of treatment are met. In this study, the dose escalation design is adopted. The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
The invention relates to the field of dressing products, and relates to micro equipment, an illumination medicine and application thereof to wound dressing. Wherein the illumination medicine comprises 1-15 parts of nano-and submicron propolis, 10-20 parts of onion extract, 20-30 parts of asiaticoside, 1-3 parts of vitamin E, 20-30 parts of cucumber extract and 30-50 parts of pericarpium Granati extract; the miniature equipment comprises a telescopic needle roller and a pulse irradiation equipment, wherein the telescopic needle roller is introduced into a liquid preparation of an illumination medicament, and the pulse irradiation equipment consists of two types of colored lights, namely pulse blue light in a wavelength range of 413-420nm and pulse red light in a wavelength range of 710-740nm. Microdevices and photopharmaceuticals may be used simultaneously in wound dressings. The photopharmaceutical combination device has good effect of promoting wound healing in clinical level. Can be used for cancerous wound, diabetic wound, various traumas and operation wound. Is a wound dressing application sterilization and disinfection device with wide market prospect.
BACKGROUND: Whole blood (WB) resuscitation is increasingly used at trauma centers. Prior studies investigating outcomes in WB versus component-only (CO) resuscitation have been limited by small cohorts, low volumes of WB resuscitation, and unbalanced CO resuscitation. This study aimed to address these limitations using data from a high-volume Level I trauma center, which adopted a WB-first resuscitation paradigm in 2018. We hypothesized that the resuscitation method, WB or balanced CO, would have no impact on patient mortality.
METHODS: A single-center, retrospective cohort study of adults presenting as a trauma activation from July 2016 through July 2021 was performed. Receipt of three or more units of WB or packed red blood cells (RBC) within the first hour of resuscitation was required for inclusion. Patients were grouped into WB versus CO resuscitation and important clinical outcomes were compared. Mortality was evaluated with Kaplan-Meier analysis, log-rank testing, and multivariable Cox proportional hazards modeling.
RESULTS: There were 180 patients in the WB group and 170 patients in the CO group. Of the 180 WB patients, 110 (61%) received only WB during the first 24 hours. The WB group received a median of 5.0 units (interquartile range, 4.0-8.0) of WB and CO group received a median of 6.0 units (interquartile range, 4.0-11.8) of RBCs during the first 24 hours of resuscitation. In the CO group, median RBC/plasma and RBC/platelet ratios approximated 1:1:1. Groups were similar in clinicopathologic characteristics including age, Injury Severity Score, mechanism of injury, and requirement for hemorrhage control interventions (WB 55% vs. CO 59%, p = 0.60). Unadjusted survival was equivalent at 24 hours ( p = 0.52) and 30 days ( p = 0.70) between both groups on Kaplan-Meier analysis with log-rank testing. On multivariable Cox regression, WB resuscitation was not independently associated with improved survival after accounting for age, Injury Severity Score, mechanism of injury, and receipt of hemorrhage control procedure (hazard ratio, 0.85; 95% confidence interval, 0.61-1.19, p = 0.34).
CONCLUSION: Balanced CO resuscitation is associated with similar mortality outcomes to that of WB based resuscitation.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
OBJECTIVE: To study the symptoms, diagnosis and treatment of internal hernias strangulated in mesenteric openings in young children.
MATERIAL AND METHODS: There were 5 children younger 3 years old with intestinal infringement in jejunal mesenteric openings (n=4) and mesentery of the vermiform process (n=1). We analyzed anamnestic, visual, ultrasound, laboratory, X-ray, and morphological data. Three patients are described.
RESULTS: Four girls had small intestine infringements in mesenteric openings. Two children underwent surgery with favorable results. Two girls died without surgery, as the diagnosis of acute intestinal obstruction was not established. In one newborn boy, small intestine loop was infringed in mesentery of the vermiform process. Surgical intervention led to recovery.
CONCLUSION: Diagnosis of internal hernias strangulated in mesenteric openings presents significant difficulties in young children due to non-specific clinical data. Prognosis depends on duration of anamnesis and timely surgical intervention.
This research study is a complex, long term investigation of the relationships between children's eating behaviors, and parent-child interaction during eating and their associations with BMI and dietary intake. It builds on earlier observational research which, like this research, had small experimental components used to classify children into different phenotypic groups based on different responses to the experimental conditions. The small activities and experiments of this follow up study constitute a trial as defined by NIH, registered here. The exploratory outcomes measured from these activities are not listed in this registration for reasons of scientific integrity. To be clear, the bigger structure of this research is essentially an observational follow up study with the same children who were previously studied as infants. The goal of the project is to identify potential future intervention targets.
For oral administration only. Administration via gastrostomy or nasogastric tubes has not been evaluated.

  1. Schedule PHEBURANE dosages at the same time as food consumption (meal or snack).
  2. Use the calibrated dosing spoon to measure PHEBURANE oral pellets. The dosing spoon is directly calibrated in grams of sodium phenylbutyrate.
  3. Swallow the coated oral pellets with a drink (e.g., water, fruit juices, protein-free infant formulas) or sprinkle onto spoonful of apple sauce or carrot puree. Do not chew PHEBURANE oral pellets directly or mix into liquids. 
  4. Swallow immediately to minimize dissolution of coating.



Administration of PHEBURANE oral pellets with other foods has not been studied and is not recommended. Additionally, administration with soft food is only recommended in patients old enough to consume soft foods.
The arm includes patients with TMP pain screening scores ≥ 3 and with diagnosis of myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to Axis I diagnostic criteria for temporomandibular disorders (DK/TMP). Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance.
The design is a randomized cross-over clinical trial following an A1-B1-B2-A2 design. In the locked condition, the 20 degree of frontal plane ankle motion is eliminated by a physical lock. The A conditions will be with the usual foot. The B conditions are randomized to the locked and unlocked investigational foot.
TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.